Hongjuan Zhang, Daniel X. He, Xinhe Feng, Mingkun Zhang*, Annie X. An, Cunxiang Ju*, Chen Jiang, Xiaolong Tu, Henry Q. X. Li, Davy X. Ouyang
*GemPharmatech
CD137 is an attractive immuno-oncology therapeutic target with multiple agonistic antibodies already in clinical testing. Clinical trials are hampered, however, by dose-limiting off-target liver toxicity with treatments using antagonistic monoclonal antibodies therapies like urelumab and utomilumab.
Developing approaches to uncouple liver toxicity from efficacy is also limited by a lack of preclinical models which can be used to assess both the efficacy and immune-related adverse events (irAE) of human CD137 agonistic antibodies. In this poster we discuss the application of a humanized CD137 knock-in mouse to assess urelumab and a range of chimeric modifications.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-26
landing_page
PDX/Databases